SCHEMBL2285511

SCHEMBL2285511

N=S(=O)(c1ccccc1)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.58
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
ALDH1A1 P00352 2/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
CA12 O43570 1/20 0.52
CA3 P07451 1/20 0.52
CA4 P22748 1/20 0.52
CA6 P23280 1/20 0.52
CA5A P35218 1/20 0.52
CA7 P43166 1/20 0.52
PLA2G7 Q13093 1/20 0.52
CA9 Q16790 1/20 0.52
CA13 Q8N1Q1 1/20 0.52
CA14 Q9ULX7 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
TSHR P16473 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
DUSP3 P51452 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11388569 0.80 NAPRT (0.57) CA1CA2ALDH1A1HSD17B10TDP1
SCHEMBL2820495 0.80 ALDH1A1 (0.58) CA1CA2ALDH1A1CA12CA3
SCHEMBL23845470 0.77 ALDH1A1 (0.54) ALDH1A1HSD17B10TDP1SMN1; SMN2CYP2C9
SCHEMBL486841 0.77 HTR6 (0.52) HTR6CA1CA2ALDH1A1HSD17B10
Benzenesulfonamide SCHEMBL13452509 0.77 SMN1; SMN2 (0.62) HTR6CA1CA2ALDH1A1HSD17B10
SCHEMBL31460982 0.77 HTR6 (0.52) HTR6CA1CA2ALDH1A1HSD17B10
SCHEMBL486787 0.77 HTR6 (0.52) HTR6CA1CA2ALDH1A1HSD17B10
SCHEMBL25408013 0.77 HTR6 (0.52) HTR6CA1CA2ALDH1A1HSD17B10
SCHEMBL486856 0.77 HTR6 (0.52) HTR6CA1CA2ALDH1A1HSD17B10
SCHEMBL8580527 0.77 CA1 (0.62) HTR6CA1CA2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116813618-A Amino-substituted imidazopyridine compound and synthesis method thereof 郑州泰基鸿诺医药股份有限公司 2023-09-29 CN claimed
US-12503446-B2 Bromodomain inhibitors Forschungszentrum Jülich GmbH (DE) 2025-12-23 US disclosed
US-20250179012-A1 SYNTHESIS OF SULFUR(VI) COMPOUNDS AND REAGENTS FOR SAME H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2025-06-05 US disclosed
WO-2025073057-A1 METHODS FOR PREPARING SULFILIMINES AND SULFOXIMINES FROM THIOETHERS USING O-(DIPHENYLPHOSPHINYL)HYDROXYL AMINE (DPPH), AND AMATOXIN ANALOGS PREPARED FROM SUCH METHODS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2025-04-10 WO disclosed
CN-118420501-A N-sulfinyl benzoyl hydrazone series compounds and preparation method thereof 浙大城市学院 2024-08-02 CN disclosed
CN-116813618-A Amino-substituted imidazopyridine compound and synthesis method thereof 郑州泰基鸿诺医药股份有限公司 2023-09-29 CN disclosed
WO-2023168108-A2 SYNTHESIS OF SULFUR(VI) COMPOUNDS AND REAGENTS FOR SAME H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-09-07 WO disclosed
CN-116239547-A Synthesis method of benzo [ i ] [1,2] thiazine-3, 7, 8-trione-1-oxygen series compound 浙大城市学院 2023-06-09 CN disclosed
CN-114133367-B Preparation method of sulfoxide imido dihydropyrone derivative 大连理工常熟研究院有限公司 2023-03-21 CN disclosed
WO-2022261427-A1 (4-(6-((2-OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)PHENYL)(IMINO)(METHYL)-LAMBDA6- SULFANONE DERIVATIVES AND SIMILAR COMPOUNDS AS MUSCARINIC ACETYLCHOLINE RECEPTOR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS VANDERBILT UNIVERSITY (US) 2022-12-15 WO disclosed
WO-1991010648-A1 DIPHENYLSULPHOXIMINE MUSCARINIC RECEPTOR ANTAGONISTS PFIZER LIMITED (GB) 1991-07-25 WO disclosed
US-4525586-A Composition and process THE UPJOHN COMPANY (US) 1985-06-25 US disclosed
EP-0035969-B1 COMPOSITION OF CATIONICALLY POLYMERISABLE MATERIAL AND A CATALYST CIBA-GEIGY AG (CH) 1985-02-13 EP disclosed
US-4420632-A PROSTAGLANDINS; ANTICOAGULANTS THE UPJOHN COMPANY (US) 1983-12-13 US disclosed
US-4349689-A Methano carbacyclin analogs THE UPJOHN COMPANY (US) 1982-09-14 US disclosed
US-4339567-A Photopolymerization by means of sulphoxonium salts CIBA-GEIGY CORPORATION (US) 1982-07-13 US disclosed
US-4306075-A Composition and process THE UPJOHN COMPANY (US) 1981-12-15 US disclosed
US-4306076-A Inter-phenylene CBA compounds THE UPJOHN COMPANY (US) 1981-12-15 US disclosed
EP-0035969-A1 Composition of cationically polymerisable material and a catalyst CIBA-GEIGY AG (CH) 1981-09-16 EP disclosed
US-4105795-A Antispasmodic substituted sulphoximides LUDWIG HEUMANN & CO. GMBH. (DE) 1978-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179012-A1 SYNTHESIS OF SULFUR(VI) COMPOUNDS AND REAGENTS FOR SAME TST, CBS, SQOR HTR6 2354/4885CA1 1942/4885CA2 2123/4885
US-12503446-B2 Bromodomain inhibitors BRDT, BRD4, BRPF3 HTR6 3390/4885CA1 4251/4885CA2 4236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.